SG11201408397SA - Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds - Google Patents
Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compoundsInfo
- Publication number
- SG11201408397SA SG11201408397SA SG11201408397SA SG11201408397SA SG11201408397SA SG 11201408397S A SG11201408397S A SG 11201408397SA SG 11201408397S A SG11201408397S A SG 11201408397SA SG 11201408397S A SG11201408397S A SG 11201408397SA SG 11201408397S A SG11201408397S A SG 11201408397SA
- Authority
- SG
- Singapore
- Prior art keywords
- lllll
- international
- san diego
- llll
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 102220240796 rs553605556 Human genes 0.000 abstract 2
- 238000000375 direct analysis in real time Methods 0.000 abstract 1
- 238000012063 dual-affinity re-targeting Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261661091P | 2012-06-18 | 2012-06-18 | |
PCT/US2013/046403 WO2013192225A1 (en) | 2012-06-18 | 2013-06-18 | Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201408397SA true SG11201408397SA (en) | 2015-01-29 |
Family
ID=49756458
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201703253XA SG10201703253XA (en) | 2012-06-18 | 2013-06-18 | Substituted pyridine azolopyrimidine-5-(6h)-one compounds |
SG11201408395WA SG11201408395WA (en) | 2012-06-18 | 2013-06-18 | Substituted pyridine azolopyrimidine - 5 - (6h) - one compounds |
SG11201408397SA SG11201408397SA (en) | 2012-06-18 | 2013-06-18 | Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201703253XA SG10201703253XA (en) | 2012-06-18 | 2013-06-18 | Substituted pyridine azolopyrimidine-5-(6h)-one compounds |
SG11201408395WA SG11201408395WA (en) | 2012-06-18 | 2013-06-18 | Substituted pyridine azolopyrimidine - 5 - (6h) - one compounds |
Country Status (18)
Country | Link |
---|---|
US (7) | US9175010B2 (zh) |
EP (3) | EP2861605B1 (zh) |
JP (2) | JP6240180B2 (zh) |
KR (2) | KR102191816B1 (zh) |
CN (2) | CN104583217B (zh) |
AU (3) | AU2013277298B2 (zh) |
BR (2) | BR112014031731B1 (zh) |
CA (2) | CA2877149C (zh) |
DK (2) | DK2861603T3 (zh) |
ES (2) | ES2715325T3 (zh) |
HK (2) | HK1208024A1 (zh) |
IL (2) | IL236232A (zh) |
IN (2) | IN2015DN00334A (zh) |
MX (2) | MX359615B (zh) |
NZ (2) | NZ703949A (zh) |
RU (2) | RU2659779C2 (zh) |
SG (3) | SG10201703253XA (zh) |
WO (2) | WO2013192225A1 (zh) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2001284792A1 (en) * | 2000-08-10 | 2002-02-25 | Cold Spring Harbor Laboratory | Augmented cognitive training |
KR102191816B1 (ko) | 2012-06-18 | 2020-12-17 | 다트 뉴로사이언스 (케이만) 엘티디. | 치환된 피리딘 아졸로피리미딘-5-(6h)-온 화합물 |
JP6396230B2 (ja) * | 2014-01-27 | 2018-09-26 | 株式会社ポーラファルマ | 使用時泡状を呈する外用医薬組成物 |
JP6396229B2 (ja) * | 2014-01-27 | 2018-09-26 | 株式会社ポーラファルマ | 使用時泡状を呈する外用医薬組成物 |
JP6396231B2 (ja) * | 2014-01-27 | 2018-09-26 | 株式会社ポーラファルマ | 使用時泡状を呈する外用医薬組成物 |
GB201406486D0 (en) * | 2014-04-10 | 2014-05-28 | Redx Pharma Ltd | Antibacterial compounds |
TW201629064A (zh) | 2014-10-10 | 2016-08-16 | H 朗德貝克公司 | 作爲pde1抑制劑之三唑並吡酮 |
JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
WO2017046603A1 (en) * | 2015-09-18 | 2017-03-23 | Redx Pharma Plc | Antibacterial compounds and new uses thereof |
TWI609870B (zh) | 2016-02-12 | 2018-01-01 | 美國禮來大藥廠 | Pde1抑制劑 |
TWI729109B (zh) | 2016-04-12 | 2021-06-01 | 丹麥商H 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
JOP20170164A1 (ar) | 2016-08-25 | 2019-01-30 | Lilly Co Eli | مشتق ترايازولو بيرازينون مفيد كمثبط لـ pde1 بشري |
CN109843884B (zh) | 2016-10-18 | 2022-03-04 | H.隆德贝克有限公司 | 作为pde1抑制剂的咪唑并吡嗪酮、吡唑并嘧啶酮和吡唑并吡啶酮 |
SG11201903061YA (en) | 2016-10-28 | 2019-05-30 | H Lundbeck As | Combination treatments comprising administration of imidazopyrazinones |
MA46611B1 (fr) | 2016-10-28 | 2020-08-31 | H Lundbeck As | Traitements combinés comprenant des imidazopyrazinones pour le traitement de troubles psychiatriques et/ou cognitifs |
US10981916B2 (en) | 2016-12-28 | 2021-04-20 | Dart Neuroscience, Llc | Substituted pyrazolopyrimidinone compounds as PDE2 inhibitors |
JP7109446B2 (ja) * | 2016-12-30 | 2022-07-29 | フリークエンシー セラピューティクス インコーポレイテッド | 幹細胞/前駆支持細胞の自己複製を誘導するための1h-ピロール-2,5-ジオン化合物およびその使用方法 |
CN110325193B (zh) * | 2017-02-23 | 2023-05-05 | 勃林格殷格翰国际有限公司 | 化合物iii的新型医学用途 |
AR112457A1 (es) | 2017-08-02 | 2019-10-30 | Lilly Co Eli | Derivados de [1,2,4]triazolo[4,3-a]pirazin-6(5h)-ona |
AR112346A1 (es) | 2017-08-10 | 2019-10-16 | Lilly Co Eli | Derivados de [1,2,4]triazolo |
AU2018373258B2 (en) | 2017-11-27 | 2023-03-02 | Dart Neuroscience, Llc | Substituted furanopyrimidine compounds as PDE1 inhibitors |
GB2575490A (en) * | 2018-07-12 | 2020-01-15 | Recordati Ind Chimica E Farmaceutica Spa | P2X3 receptor antagonists |
EP4017858A4 (en) * | 2019-08-22 | 2023-09-27 | Intra-Cellular Therapies, Inc. | ORGANIC COMPOUNDS |
CN112778311B (zh) * | 2019-11-01 | 2024-06-04 | 上海翰森生物医药科技有限公司 | 含氮并环类衍生物抑制剂、其制备方法和应用 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3046366A1 (de) * | 1980-12-09 | 1982-07-08 | Bayer Ag, 5090 Leverkusen | Tricyclische cytosinderivate zur verwendung in arzneimitteln und verfahren zu ihrer herstellung |
DE3146599A1 (de) | 1981-11-25 | 1983-07-07 | Basf Ag, 6700 Ludwigshafen | Neue triazolochinazoline, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen |
EP0181282A1 (de) | 1984-10-01 | 1986-05-14 | Ciba-Geigy Ag | Triazolochinazolinverbindungen |
JPS62135475A (ja) * | 1985-09-30 | 1987-06-18 | チバ−ガイギ− アクチエンゲゼルシヤフト | 2−置換−e−融合−〔1,2,4〕トリアゾロ−〔1,5−C〕ピリミジン |
EP0217748B1 (en) * | 1985-09-30 | 1991-02-06 | Ciba-Geigy Ag | 2-Substituted-e-fused-[1,2,4,]triazolo-[1,5-c]pyrimidines pharmaceutical compositions and uses thereof |
US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
FR2659329B1 (fr) | 1990-03-09 | 1994-06-03 | Adir | Nouveaux derives d'imidazo [1,2-c] quinazoline, leur procede de preparation et les compositions pharmaceutiques les renfermant. |
JP2002501892A (ja) * | 1998-01-29 | 2002-01-22 | セプラコア インコーポレーテッド | 光学的に純粋な(−)−ビュープロピオンの薬学的使用 |
ES2166270B1 (es) * | 1999-07-27 | 2003-04-01 | Almirall Prodesfarma Sa | Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona. |
DE10012373A1 (de) * | 2000-03-14 | 2001-09-20 | Dresden Arzneimittel | Verwendung von Pyrido[3,2-e]-pyrazinonen als Inhibitoren der Phosphodiesterase 5 zur Therapie von erektiler Dysfunktion |
US8153646B2 (en) | 2000-08-10 | 2012-04-10 | Dart Neuroscience (Cayman) Ltd. | Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation |
AU2001284792A1 (en) | 2000-08-10 | 2002-02-25 | Cold Spring Harbor Laboratory | Augmented cognitive training |
US7868015B2 (en) | 2000-08-10 | 2011-01-11 | Cold Spring Harbor Laboratory | Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit |
FR2897061B1 (fr) | 2006-02-03 | 2010-09-03 | Sanofi Aventis | Derives de n-heteroaryl-carboxamides tricycliques contenant un motif benzimidazole, leur preparation et leur application en therapeutique. |
JP5453086B2 (ja) * | 2006-06-06 | 2014-03-26 | イントラ−セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
US20100029697A1 (en) | 2007-03-28 | 2010-02-04 | Debenham John S | Substituted pyrido[3,2-e][1,2,4]triazolo[4,3-c]pyrimidine derivatives as cannabinoid-1 receptor modulators |
AU2008254907A1 (en) | 2007-05-15 | 2008-11-27 | Helicon Therapeutics, Inc. | Methods of identifying genes involved in memory formation using small interfering RNA(siRNA) |
US20100203624A1 (en) | 2007-09-26 | 2010-08-12 | Ge Healthcare Bioscience Bioprocess Corp. | Three dimensional disposable bioreactor |
SI2240490T1 (sl) | 2007-12-06 | 2014-02-28 | Takeda Pharmaceutical Company Limited | Organske spojine |
EP2219646A4 (en) * | 2007-12-21 | 2010-12-22 | Univ Rochester | METHOD FOR MODIFYING THE LIFETIME OF EUKARYOTIC ORGANISMS |
WO2010065149A1 (en) | 2008-12-06 | 2010-06-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
CN102223799A (zh) * | 2008-12-06 | 2011-10-19 | 细胞内治疗公司 | 有机化合物 |
JP2012518685A (ja) | 2009-02-25 | 2012-08-16 | イントラ−セルラー・セラピーズ・インコーポレイテッド | 眼障害のためのpde1阻害剤 |
EP2434895A4 (en) | 2009-05-13 | 2013-08-07 | Intra Cellular Therapies Inc | ORGANIC CONNECTIONS |
JP5879336B2 (ja) * | 2010-05-31 | 2016-03-08 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 有機化合物 |
US9371327B2 (en) | 2010-05-31 | 2016-06-21 | Intra-Cellular Therapies, Inc. | PDE1 inhibitor compounds |
TW201206937A (en) | 2010-05-31 | 2012-02-16 | Intra Cellular Therapies Inc | Organic compounds |
EP2576551A4 (en) * | 2010-05-31 | 2014-04-16 | Intra Cellular Therapies Inc | ORGANIC COMPOUNDS |
WO2012171016A1 (en) | 2011-06-10 | 2012-12-13 | Intra-Cellular Therapies, Inc. | Organic compounds |
KR102191816B1 (ko) * | 2012-06-18 | 2020-12-17 | 다트 뉴로사이언스 (케이만) 엘티디. | 치환된 피리딘 아졸로피리미딘-5-(6h)-온 화합물 |
-
2013
- 2013-06-18 KR KR1020157001198A patent/KR102191816B1/ko active IP Right Grant
- 2013-06-18 EP EP13807708.6A patent/EP2861605B1/en active Active
- 2013-06-18 US US13/920,974 patent/US9175010B2/en active Active
- 2013-06-18 IN IN334DEN2015 patent/IN2015DN00334A/en unknown
- 2013-06-18 IN IN335DEN2015 patent/IN2015DN00335A/en unknown
- 2013-06-18 SG SG10201703253XA patent/SG10201703253XA/en unknown
- 2013-06-18 CN CN201380043254.5A patent/CN104583217B/zh active Active
- 2013-06-18 RU RU2015100209A patent/RU2659779C2/ru active
- 2013-06-18 WO PCT/US2013/046403 patent/WO2013192225A1/en active Application Filing
- 2013-06-18 JP JP2015518522A patent/JP6240180B2/ja active Active
- 2013-06-18 BR BR112014031731-3A patent/BR112014031731B1/pt active IP Right Grant
- 2013-06-18 WO PCT/US2013/046415 patent/WO2013192229A1/en active Application Filing
- 2013-06-18 MX MX2014015737A patent/MX359615B/es active IP Right Grant
- 2013-06-18 US US14/408,942 patent/US9284335B2/en active Active
- 2013-06-18 KR KR1020157001117A patent/KR102087756B1/ko active IP Right Grant
- 2013-06-18 US US14/408,927 patent/US9499562B2/en active Active
- 2013-06-18 SG SG11201408395WA patent/SG11201408395WA/en unknown
- 2013-06-18 CA CA2877149A patent/CA2877149C/en active Active
- 2013-06-18 BR BR112014031730-5A patent/BR112014031730B1/pt active IP Right Grant
- 2013-06-18 AU AU2013277298A patent/AU2013277298B2/en active Active
- 2013-06-18 CN CN201380043291.6A patent/CN104583213B/zh active Active
- 2013-06-18 RU RU2015100213A patent/RU2653054C2/ru active
- 2013-06-18 EP EP18213541.8A patent/EP3489238B8/en active Active
- 2013-06-18 MX MX2014015740A patent/MX357320B/es active IP Right Grant
- 2013-06-18 JP JP2015518523A patent/JP6129960B2/ja active Active
- 2013-06-18 NZ NZ703949A patent/NZ703949A/en unknown
- 2013-06-18 ES ES13807565T patent/ES2715325T3/es active Active
- 2013-06-18 DK DK13807565.0T patent/DK2861603T3/en active
- 2013-06-18 EP EP13807565.0A patent/EP2861603B1/en active Active
- 2013-06-18 AU AU2013277294A patent/AU2013277294C1/en active Active
- 2013-06-18 DK DK18213541.8T patent/DK3489238T3/da active
- 2013-06-18 SG SG11201408397SA patent/SG11201408397SA/en unknown
- 2013-06-18 NZ NZ703950A patent/NZ703950A/en unknown
- 2013-06-18 ES ES18213541T patent/ES2904267T3/es active Active
- 2013-06-18 CA CA2877146A patent/CA2877146C/en active Active
-
2014
- 2014-12-14 IL IL236232A patent/IL236232A/en active IP Right Grant
- 2014-12-14 IL IL236233A patent/IL236233A/en active IP Right Grant
-
2015
- 2015-09-02 HK HK15108624.0A patent/HK1208024A1/zh unknown
- 2015-09-02 HK HK15108586.6A patent/HK1208023A1/zh unknown
- 2015-09-14 US US14/853,856 patent/US9533996B2/en active Active
-
2016
- 2016-11-17 US US15/354,804 patent/US10092575B2/en active Active
- 2016-12-29 US US15/394,058 patent/US10105367B2/en active Active
-
2017
- 2017-12-07 AU AU2017272245A patent/AU2017272245B2/en active Active
-
2018
- 2018-10-18 US US16/164,726 patent/US10376514B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201408397SA (en) | Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds | |
SG11201810983PA (en) | Novel heterocyclic derivatives useful as shp2 inhibitors | |
SG11201806861SA (en) | Combination therapy with anti-cd73 antibodies | |
SG11201807252QA (en) | Anti-lag-3 antibodies | |
SG11201811184UA (en) | Lag -3 binding members | |
SG11201809559UA (en) | Substituted pyridines as inhibitors of dnmt1 | |
SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
SG11201803701YA (en) | Methods and compositions for gene editing in hematopoietic stem cells | |
SG11201806302RA (en) | Inhibitors of receptor-interacting protein kinase 1 | |
SG11201810034XA (en) | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | |
SG11201804132UA (en) | Eif4-a-inhibiting compounds and methods related thereto | |
SG11201408750VA (en) | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | |
SG11201407268SA (en) | Nuclear transport modulators and uses thereof | |
SG11201804312RA (en) | Microbubble-chemotherapeutic agent complex for sonodynamic therapy | |
SG11201407669QA (en) | Methods for improving safety of blood-brain barrier transport | |
SG11201407220YA (en) | N-alkyltriazole compounds as lpar antagonists | |
SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
SG11201407537YA (en) | Mutant selectivity and combinations of a phosphoinositide 3 kinase inhibitor compound and chemotherapeutic agents for the treatment of cancer | |
SG11201407747QA (en) | A method and apparatus for facilitating the management of health and security | |
SG11201908179UA (en) | Aryl cyclopropyl-amino-isoquinolinyl amide compounds | |
SG11201403402VA (en) | Compounds | |
SG11201804668UA (en) | Bicyclic inhibitors of pad4 | |
SG11201407370QA (en) | Humanized il-7 rodents | |
SG11201404854RA (en) | Aerosol-generating article having a flavour-generating component | |
SG11201407372UA (en) | Nampt inhibitors |